Filing Details

Accession Number:
0001725160-20-000057
Form Type:
4
Zero Holdings:
No
Publication Time:
2020-12-08 20:37:34
Reporting Period:
2020-12-04
Accepted Time:
2020-12-08 20:37:34
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1725160 Zentalis Pharmaceuticals Inc. ZNTL () 4
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1377952 Y Anthony Sun C/O Zentalis Pharmaceuticals, Inc.
530 Seventh Avenue, Suite 2201
New York NY 10018
President & Ceo Yes Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Disposition 2020-12-04 18,413 $50.76 2,074,567 No 4 S Direct
Common Stock Disposition 2020-12-04 21,356 $51.17 2,053,211 No 4 S Direct
Common Stock Disposition 2020-12-07 657 $50.84 2,052,554 No 4 S Direct
Common Stock Disposition 2020-12-07 5,350 $52.53 2,047,204 No 4 S Direct
Common Stock Disposition 2020-12-07 27,446 $53.71 2,019,758 No 4 S Direct
Common Stock Disposition 2020-12-07 2,153 $54.39 2,017,605 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 S Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
Reported Non-Derivative Holdings
Sec. Name Remaning Holdings Nature of Ownership Explanation
Common Stock 974,302 Indirect By Essex Group International, LLC
Footnotes
  1. The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading arrangement adopted by the Reporting Person. Shares sold to satisfy withholding tax obligations upon the vesting of restricted stock units.
  2. The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $50.02 to $51.01. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  3. The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $51.02 to $52.00. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  4. The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $50.53 to $51.50. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  5. The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $52.15 to $53.13. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  6. The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $53.15 to $54.14. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  7. The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $54.15 to $54.89. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.